Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents

Grants

Funding Acknowledgements

Bruce D. Cheson: AbbVie, Acerta, Gilead, Pharmacyclics, Roche-Genentech (C/A, RF); Sari Heitner Enschede: AbbVie (E, OI); Elisa Cerri: AbbVie (E, OI); Monali Desai: AbbVie (E, OI); Jalaja Potluri: AbbVie (E, OI); Nicole Lamanna: AbbVie, Celgene, Genentech, Gilead, Janssen, Pharmacyclics (SAB); AbbVie, Genentech, Gilead, Infinity, ProNai (RF); Constantine Tam: AbbVie, Roche (C/A).